A Silicon Valley company being closely watched in the race to develop liquid biopsies said Wednesday that it was launching a large clinical trial — one it hopes will support a premarket approval submission for a test for colon cancer.

Guardant Health said it will use its LUNAR test to try to find mutations in tumors that have already been diagnosed. Its study will include 10,000 patients between the ages of 45 and 84 who are at average risk of colon cancer who are going to get a colonoscopy. They will also receive Guardant’s blood test, which will allow researchers to see if they have colon cancer or pre-cancerous polyps.

Details of the trial were posted to ClinicalTrials.gov, a government website that makes information on clinical trials available.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy